Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer

Francesco Grossi, Cesare Gridelli, Marianna Aita, Filippo De Marinis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Owing to the slow but sustained progress made in lung cancer treatment over the last 20 years, several therapeutic options are now available in the first-line setting as well as for patients who have progressed after one or more previous lines of treatment. Considering the growing array of choices currently confronting clinicians involved in the treatment of advanced non-small cell lung cancer (NSCLC), an effort should be made to define the optimal treatment option in each disease setting and to identify a logical therapeutic strategy after initial disease progression. This is especially crucial in the management of young, fit patients, who may be suitable candidates for two or more lines of therapy. At present, a rational treatment strategy for advanced NSCLC may be designed on the basis of patient clinicopathological features and rely on evidence from large, well-conducted clinical trials. In a near future the results of prospective validation studies will provide more sophisticated approaches for the classification of lung cancer patients, allowing clinicians to make individualised treatment decisions based on tumour molecular profile and on novel, more refined predictive/prognostic factors.

Original languageEnglish
Pages (from-to)16-26
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume67
Issue number1
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Lung Neoplasms
Validation Studies
Disease Progression
Clinical Trials
Prospective Studies

Keywords

  • Advanced non-small cell lung cancer
  • Biological drugs
  • First-line chemotherapy
  • Second-line therapy
  • Third-line therapy
  • Treatment strategy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. / Grossi, Francesco; Gridelli, Cesare; Aita, Marianna; De Marinis, Filippo.

In: Critical Reviews in Oncology/Hematology, Vol. 67, No. 1, 07.2008, p. 16-26.

Research output: Contribution to journalArticle

@article{d118d5a986c248e99eaf224e9a52fd83,
title = "Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer",
abstract = "Owing to the slow but sustained progress made in lung cancer treatment over the last 20 years, several therapeutic options are now available in the first-line setting as well as for patients who have progressed after one or more previous lines of treatment. Considering the growing array of choices currently confronting clinicians involved in the treatment of advanced non-small cell lung cancer (NSCLC), an effort should be made to define the optimal treatment option in each disease setting and to identify a logical therapeutic strategy after initial disease progression. This is especially crucial in the management of young, fit patients, who may be suitable candidates for two or more lines of therapy. At present, a rational treatment strategy for advanced NSCLC may be designed on the basis of patient clinicopathological features and rely on evidence from large, well-conducted clinical trials. In a near future the results of prospective validation studies will provide more sophisticated approaches for the classification of lung cancer patients, allowing clinicians to make individualised treatment decisions based on tumour molecular profile and on novel, more refined predictive/prognostic factors.",
keywords = "Advanced non-small cell lung cancer, Biological drugs, First-line chemotherapy, Second-line therapy, Third-line therapy, Treatment strategy",
author = "Francesco Grossi and Cesare Gridelli and Marianna Aita and {De Marinis}, Filippo",
year = "2008",
month = "7",
doi = "10.1016/j.critrevonc.2007.12.002",
language = "English",
volume = "67",
pages = "16--26",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer

AU - Grossi, Francesco

AU - Gridelli, Cesare

AU - Aita, Marianna

AU - De Marinis, Filippo

PY - 2008/7

Y1 - 2008/7

N2 - Owing to the slow but sustained progress made in lung cancer treatment over the last 20 years, several therapeutic options are now available in the first-line setting as well as for patients who have progressed after one or more previous lines of treatment. Considering the growing array of choices currently confronting clinicians involved in the treatment of advanced non-small cell lung cancer (NSCLC), an effort should be made to define the optimal treatment option in each disease setting and to identify a logical therapeutic strategy after initial disease progression. This is especially crucial in the management of young, fit patients, who may be suitable candidates for two or more lines of therapy. At present, a rational treatment strategy for advanced NSCLC may be designed on the basis of patient clinicopathological features and rely on evidence from large, well-conducted clinical trials. In a near future the results of prospective validation studies will provide more sophisticated approaches for the classification of lung cancer patients, allowing clinicians to make individualised treatment decisions based on tumour molecular profile and on novel, more refined predictive/prognostic factors.

AB - Owing to the slow but sustained progress made in lung cancer treatment over the last 20 years, several therapeutic options are now available in the first-line setting as well as for patients who have progressed after one or more previous lines of treatment. Considering the growing array of choices currently confronting clinicians involved in the treatment of advanced non-small cell lung cancer (NSCLC), an effort should be made to define the optimal treatment option in each disease setting and to identify a logical therapeutic strategy after initial disease progression. This is especially crucial in the management of young, fit patients, who may be suitable candidates for two or more lines of therapy. At present, a rational treatment strategy for advanced NSCLC may be designed on the basis of patient clinicopathological features and rely on evidence from large, well-conducted clinical trials. In a near future the results of prospective validation studies will provide more sophisticated approaches for the classification of lung cancer patients, allowing clinicians to make individualised treatment decisions based on tumour molecular profile and on novel, more refined predictive/prognostic factors.

KW - Advanced non-small cell lung cancer

KW - Biological drugs

KW - First-line chemotherapy

KW - Second-line therapy

KW - Third-line therapy

KW - Treatment strategy

UR - http://www.scopus.com/inward/record.url?scp=44949185573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949185573&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.12.002

DO - 10.1016/j.critrevonc.2007.12.002

M3 - Article

VL - 67

SP - 16

EP - 26

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -